AWM
RCUS icon

Avior Wealth Management’s Arcus Biosciences RCUS Stock Holding History

Avior Wealth Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10
Closed -$188 – 3389
2024
Q1 		$188 Buy
+10
New +$173 ﹤0.01% 2896

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Avior Wealth Management's RCUS Position: Q2 2024 in Review

Avior Wealth Management sold out of Arcus Biosciences (RCUS) in Q2 2024, closing a stake of 10 shares — an estimated $188 sold.

Avior Wealth Management first reported a position in RCUS in Q1 2024 and held it in 1 quarter. The position peaked at $188 in Q1 2024. 193 funds tracked by Wall St. Rank hold RCUS as of Q2 2024.

  • Avior Wealth Management reported no remaining Arcus Biosciences position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 10 Arcus Biosciences shares in Q2 2024, an estimated $188.
  • Avior Wealth Management first reported a position in Arcus Biosciences in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Arcus Biosciences position peaked at $188 in Q1 2024.
  • 193 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.